The level of ADAM12-S in maternal serum is an early first-trimester marker of fetal trisomy 18.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
The level of ADAM12-S in maternal serum is an early first-trimester marker of fetal trisomy 18. / Laigaard, Jennie; Christiansen, Michael; Frohlich, Camilla; Pedersen, Bent Nøorgaard; Ottesen, Bent; Wewer, Ulla M.
I: Prenatal Diagnosis, Bind 25, Nr. 1, 2005, s. 45-6.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - The level of ADAM12-S in maternal serum is an early first-trimester marker of fetal trisomy 18.
AU - Laigaard, Jennie
AU - Christiansen, Michael
AU - Frohlich, Camilla
AU - Pedersen, Bent Nøorgaard
AU - Ottesen, Bent
AU - Wewer, Ulla M
N1 - Keywords: ADAM Proteins; Adult; Biological Markers; Chromosomes, Human, Pair 18; Early Diagnosis; Enzyme-Linked Immunosorbent Assay; Female; Humans; Membrane Proteins; Metalloendopeptidases; Pregnancy; Pregnancy Trimester, First; Prenatal Diagnosis; Retrospective Studies; Trisomy
PY - 2005
Y1 - 2005
N2 - BACKGROUND: ADAM12-S is a pregnancy-associated insulin-like growth factor binding protein-3 (IGFBP-3) and IGFBP-5 protease present in human gestational serum. Recently, maternal serum levels of ADAM12-S were found to be markedly reduced during the first trimester of pregnancies with a Down syndrome (DS) fetus. On the basis of this finding, it was suggested that ADAM12-S might be a useful maternal serum marker of fetal chromosomal disease. OBJECTIVE: Retrospective examination of the use of ADAM12-S as a marker for fetal trisomy 18. METHOD: Serum samples were obtained from ten women during the first semester of their pregnancies with fetuses that had trisomy 18. An ELISA was used to determine the levels of ADAM12 in maternal serum. Results were compared to ADAM12-S levels, previously measured in the serum of 170 women carrying normal pregnancies during the first trimester. RESULTS: In all cases, the ADAM12-S concentration in maternal serum samples was lower in trisomy 18 pregnancies than in normal pregnancies, with a median multiple of the median (MoM) of 0.28 (p < 0.001) CONCLUSION: A reduced concentration of ADAM12-S in maternal serum is a promising marker for foetal trisomy 18, as well as for DS.
AB - BACKGROUND: ADAM12-S is a pregnancy-associated insulin-like growth factor binding protein-3 (IGFBP-3) and IGFBP-5 protease present in human gestational serum. Recently, maternal serum levels of ADAM12-S were found to be markedly reduced during the first trimester of pregnancies with a Down syndrome (DS) fetus. On the basis of this finding, it was suggested that ADAM12-S might be a useful maternal serum marker of fetal chromosomal disease. OBJECTIVE: Retrospective examination of the use of ADAM12-S as a marker for fetal trisomy 18. METHOD: Serum samples were obtained from ten women during the first semester of their pregnancies with fetuses that had trisomy 18. An ELISA was used to determine the levels of ADAM12 in maternal serum. Results were compared to ADAM12-S levels, previously measured in the serum of 170 women carrying normal pregnancies during the first trimester. RESULTS: In all cases, the ADAM12-S concentration in maternal serum samples was lower in trisomy 18 pregnancies than in normal pregnancies, with a median multiple of the median (MoM) of 0.28 (p < 0.001) CONCLUSION: A reduced concentration of ADAM12-S in maternal serum is a promising marker for foetal trisomy 18, as well as for DS.
U2 - 10.1002/pd.1029
DO - 10.1002/pd.1029
M3 - Journal article
C2 - 15662668
VL - 25
SP - 45
EP - 46
JO - Prenatal Diagnosis
JF - Prenatal Diagnosis
SN - 0197-3851
IS - 1
ER -
ID: 5259693